

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): An antibody capable of binding to the FK778 substance.

Claim 2 (Original): The antibody of Claim 1, which is a polyclonal antibody.

Claim 3 (Original): The antibody of Claim 2, wherein the class of said polyclonal antibody is IgG.

Claim 4 (Original): The antibody of Claim 1, which is a monoclonal antibody.

Claim 5 (Original): The antibody of Claim 4, which is a monoclonal antibody produced by a hybridoma cell line resulting from cell fusion between an cell producing antibodies capable of the FK778 substance from an animal and a myeloma cell.

Claim 6 (Original): The antibody of Claim 5, wherein said cell producing antibodies capable of the FK778 substance is a spleen cell line.

Claim 7 (Original): The antibody of Claim 5 wherein said animal is a mouse.

Claim 8 (Currently Amended): The antibody of ~~Claims 4, 5, 6 or 7~~ Claim 4, wherein said class of the monoclonal antibody is IgG.

Claim 9 (Original): A highly-sensitive immunoassay method for the FK778 substance, which comprises immobilizing an antibody capable of binding to the FK778

substance, allowing the FK778 substance contained in a sample and the FK778 substance labeled by detectable substance to react competitively with said immobilized antibody and detecting said labeled substance bound to said immobilized antibody.

Claim 10 (Original): A highly-sensitive immunoassay method for the FK778 substance, which comprises using a first antibody capable of binding to the FK778 substance and an immobilized second antibody capable of binding to said first antibody, allowing the FK778 substance contained in a sample and the FK778 substance labeled by a detectable substance to react competitively with said first antibody and detecting said labeled FK778 substance bound to said first antibody bound in turn to said second antibody.

Claim 11 (Original): A highly-sensitive immunoassay method for the FK778 substance, which comprises using a first antibody labeled by a first detectable substance, which is capable of binding to the FK778 substance, the FK778 substance labeled by a second detectable substance, and an immobilized second antibody capable of binding to said second detectable substance, allowing said FK778 substance contained in a sample and the FK778 substance labeled by said second detectable substance to react competitively with said first antibody and detecting said first antibody bound to said labeled FK778 substance whose said second detecting substance is bound to said second antibody.

Claim 12 (Currently Amended): The highly-sensitive immunoassay method of ~~any one of Claims 9-11~~ Claim 9, wherein said first antibody is a polyclonal antibody.

Claim 13 (Currently Amended): The highly-sensitive immunoassay method of ~~any one of Claims 9-11~~ Claim 9, wherein said first antibody is a monoclonal antibody.

Claim 14 (Currently Amended): The highly-sensitive immunoassay method of ~~any one of Claims 9-11~~ Claim 9, wherein said second antibody is immobilized on a plate.

Claim 15 (Original): A test kit for assaying the amount of the FK778 in a sample, comprising an antibody capable of binding to the FK778 substance and the FK778 substance labeled by detectable substance.

Claim 16 (Original): The test kit of Claim 15, wherein said antibody capable of binding to the FK778 substance is a monoclonal antibody.

Claim 17 (Original): The test kit of Claim 15 which further comprises a known quantity of the FK778 substance as a standard.

Claim 18 (Currently Amended): The test kit of ~~any one of Claims 15-17~~ Claim 15, which further comprises an antibody, which can bind to said antibody capable of binding to the FK778 substance, or an antibody, which can bind to said detectable substance labeling said FK778 substance.